Library · Oncology, infection & imaging · Prostate cancer PET imaging
Flotufolastat F-18
18F-rhPSMA-7.3, Posluma
FDA-approved (May 2023) radiohybrid PSMA-targeted PET imaging agent for prostate cancer, with high PSMA binding affinity and unusually low bladder activity. Improves visualization of pelvic lesions, especially after prostatectomy or with recurrence, and works even at low PSA levels.
Research score 89/100. Reference only, not a dose.
- Diagnostic Imaging
- US status
- Prescription Only - Diagnostic
- Approval
- FDA Approved (2023)
- Evidence
- LIGHTHOUSE and SPOTLIGHT Phase 3 trials: high correct detection rate, clinically meaningful upstaging, effective at low PSA levels
- Research score
- 89 / 100
- Indication
- PET imaging of PSMA-positive prostate cancer lesions
- Origin
- United States
- Source category
- Diagnostic & Imaging
- Status group
- Approved / prescription
Mechanism
Binds PSMA on prostate cancer cells and is taken up into them; its fluorine-18 label emits positrons for PET imaging.
Safety file
Well tolerated, typical for PET radiopharmaceuticals.
- Minimal - standard for radiopharmaceutical imaging